DexCom Q2 Income Rises 25.7% to $179.8mln, Revenue Up 15.2%

DexCom Inc. reported Q2 income of $179.8 million, or $0.45 per share, up from $143.5 million, or $0.35 per share, last year. Excluding items, adjusted earnings were $192.8 million or $0.48 per share. Revenue rose 15.2% to $1.157 billion from $1.004 billion last year. Full-year revenue guidance is $4.6-$4.625 billion.

Title: DexCom Inc. Reports Strong Q2 Earnings, Raises Full-Year Revenue Guidance

San Diego, July 2, 2025 - DexCom Inc. (NASDAQ: DXCM) reported its second-quarter (Q2) financial results, which exceeded analyst expectations. The company's adjusted earnings per share (EPS) of $0.48, up from $0.45 in the same period last year, were driven by a 15.2% increase in revenue to $1.157 billion, compared to $1.004 billion in Q2 2024. Despite the strong performance, shares of DXCM fell by 4% in post-market trading [1].

Key highlights from the Q2 report include:

- Revenue Growth: Revenue climbed 15.2% year-over-year (YoY) to $1.157 billion, surpassing the consensus forecast of $1.12 billion [1].
- International Expansion: International revenue grew 16% to $316.1 million, while U.S. revenue increased 15% to $841 million [2].
- Sensor and Other Revenue: This segment, representing 97% of total revenue, jumped 18% YoY to $1.12 billion, offsetting a 31% decline in hardware revenue [1].
- FDA Clearance: The company received FDA clearance for the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System, extending the wear time of the company’s sensors [1].
- CEO Transition: DexCom announced that Jake Leach will become CEO effective January 1, 2026, succeeding Kevin Sayer, who will remain as executive chairman [1].

Full-Year Guidance: DexCom raised its full-year 2025 revenue guidance to $4.6-$4.625 billion, representing a 14-15% growth compared to the previous forecast of $4.6 billion. The company maintained its non-GAAP gross profit margin guidance of approximately 62% and operating margin of about 21% [1].

Clinical Advancements: During the quarter, DexCom showcased extensive clinical evidence at the American Diabetes Association’s 85th Scientific Sessions, including new data demonstrating the benefits of Dexcom CGM usage for gestational diabetes and for people with type 2 diabetes who are not using insulin [3].

Cash Position: As of June 30, 2025, DexCom held $2.93 billion in cash, cash equivalents, and marketable securities, providing significant financial and strategic flexibility for the company’s future growth [3].

The company's strong Q2 results and the upcoming launch of the Dexcom G7 15 Day CGM System are expected to drive continued growth in the second half of 2025. The leadership transition to Jake Leach, who has been with the company for 21 years, is seen as a positive step to ensure continuity and growth.

References:
[1] https://www.investing.com/news/earnings/dexcom-posts-strong-q2-results-announces-ceo-change-shares-fall-4-93CH-4161129
[2] https://www.drugdeliverybusiness.com/dexcom-raises-guidance-q2-2025/
[3] https://www.stocktitan.net/news/DXCM/dexcom-reports-second-quarter-2025-financial-results-updates-full-6xpw0min5sgb.html